Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research
KCNA5 gene-encoded Kv1.5 potassium channel is a subtype of Kv1 potassium channel. The channel consists of α and β subunits; four identical αsubunits form a homologous tetramer, forming the pore region and voltage-sensitive area of Kv1.5 channel complex. Each α subunit contains six transmembrane protein molecule areas (S1 to S6), respectively, constituting the subjects of voltage-gated channels, N and C-terminal subunit. β subunit plays a supporting role, maintaining the stability of Kvl.5 channel as a chaperone together with associated membrane protein.
Kv1.5 Channel Function in Physiological and Pathological Conditions
Kv1.5 channel is expressed in many cell types in the human body, including atrial myocytes, pulmonary arterial smooth muscle cells (PASMCs), GH3 pituitary cells, oligodendrocyte precursor cells, macrophages, somato dendritic Purkinje cells of the cerebellum and cancer cells. Besides, the Kv1.5 channel is of particular importance in O2-sensitive tissues, as it possesses an O2-sensitive channel and its expression, at both a protein and transcript level, is directly altered by oxidative factors, mainly HIF-1α and hydrogen peroxide (H2O2). Therefore, due to its voltage and oxygen-sensitivity the Kv1.5 channel has a dynamic role in physiologic and pathophysiological states that are associated with ROS and oxidative stress. It was recently shown that exposure of neuronal cells to acute hypoxia and glucose deprivation leads to apoptosis and that this ischemia-induced cell death is associated with upregulation of Kv1.5 expression. Several reports show that Kv1.5 expression is reduced in human cancers, and in gliomas, loss of expression is directly correlated with tumor aggression, suggesting that loss of the channel might contribute to tumor progression. Moreover, recent studies demonstrated that restoration of normal mitochondrial function and redox tension by use of the pyruvate dehydrogenase kinase inhibitor dichloroacetate (DCA) resulted in derepression of KCNA5 transcription and induction of Kv1.5-dependent apoptosis.
Kv1.5 and Atrium
In the cardiovascular system, specifically in the human atrium, Kv1.5 underlies the ultra-rapid delayed recitifier current (IKur), important for atrial repolarization and action potential duration. Therefore, the Kv1.5 channel is important for returning the membrane potential of atrial myocytes from a depolarized state (~52 mV) back towards its resting membrane potential (~-80 mV). In atrial myocytes, the Kv1.5 channel current is activated at potentials in the range of -20 mV to +50 mV. Kv1.5 plays an important role in atrial fibrillation (AF). AF is the most common cardiac arrhythmia present in the population. Shortening of the atrial effective refractory period of the atrium is an important factor in acute and persistent AF. An early study established that patients in chronic AF have electrophysiological and physiological remodeling and a consequence of this remodeling is the down-regulation of Kv1.5 channel expression. One aspect associated with structural and electrical remodeling of the heart in AF, is the excessive production of ROS .Furthermore, the activation of Kv1.5 reduces action potential duration and leads to the shortening of the atrial refractory period. In particular, it is thought that initial activation of the Kv1.5 channel in acute AF contributes to the continuation of AF, leading to chronic AF and the eventual down-regulation of the Kv1.5 channel.
Kv1.5 and Pulmonary Vasculature
PASMCs rely on Kv channels, in particular the Kv1.5 channel, to determine resting membrane potential and the concentration of cytosolic free Ca2+. In the pulmonary vasculature, exposure to acute hypoxia inhibits Kv channels, increases cytosolic Ca2+ depolarizes the PASMCs and causes pulmonary vasoconstriction. Hypoxic pulmonary vasoconstriction is mediated by the inhibition of Kv potassium channels in PASMCs, predominantly via acute down-regulation of the O2-sensitive Kv1.5 channel. In PAH, conditions of acute and chronic hypoxia result in the significant down-regulation of Kv1.5 channel expression and the Kv1.5-encoding gene transcript KCNA5. Therefore, loss of Kv1.5 expression in is a contributing factor in the pathogenesis of PAH. Recently, it was discovered that the Kv1.5 channel is part of a key pathway, the mitochondria-ROS-HIF-Kv pathway, whose disruption contributes to the development of polycyclic aromatic hydrocarbon (PAH). It was elucidated that under hypoxic conditions, HIF-1 represses KCNA5 and ROS withdrawal inhibits the opening of Kv1.5 channels. This results in pulmonary vasoconstriction, the eventual hyperpolarization of the mitochondria and ultimately disrupts the mitochondria- ROS-HIF-Kv pathway. Furthermore, re-introducing the Kv1.5 channel improves pulmonary hypertension, as it restores the O2-sensitive current and reduces pulmonary vascular resistance. And the Kv1.5 channel also underlies mitochondrial-mediated cell death in PAH, due to its involvement in the mitochondria-ROS-HIF-Kv path way and the discovery that the pro-apoptotic activator cytochrome-c activates Kv channels, while the anti-apoptotic bcl-2 inhibits Kv channels.
Kv1.5 and Cell Proliferation and Apoptosis
The Kv1.5 channel has been shown to regulate the G1/S transition in the cell cycle. Several reports showed that DNA methylation and repression of KCNA5 contribute to cell-cycle progression and that reversion of promoter methylation and KCNA5 de-repression is associated with growth inhibition and cell-cycle arrest. Moreover, specific pharmacologic inhibition of the Kv1.5 channel function partially restores proliferation in Ewing sarcoma cells that have been exposed to decitabine. Reactivation of silenced Kv1.5 channels can inhibit cancer proliferation. It was discovered that Kv1.5 inhibited skeletal muscle cell proliferation at the G1/S transition, through a mechanism that increased cyclin-dependent kinase inhibitors p21 and p27 and decreased expression of cyclins A and D1. As Kv1.5 and KCNA5 expression are down-regulated in many human cancers (e.g. glioblastoma and lymphoma). In lymphocytes, down-regulation of Kv1.5 expression prevented apoptosis, while in several cancer cell lines, including M059K (glioblastoma), A549 (non-small-cell lung) and MCF-7 (breast) cancer cells, reactivation of the Kv1.5 channel induced apoptosis. Besides, in the cell line study it was discovered that the transcription factor, NFAT directly represses KCNA5, and release of this repression leads to apoptotic cell death.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.